All In Biotech

Drug Trial Radar · NCT00789555

Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis

Safety of PATANASE® Nasal Spray in Patients With Perennial Allergic Rhinitis

Last checked: Nov 19, 2026Latest source record: Feb 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,260 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,260

Actual

Start

Nov 2008

Primary completion

Jan 2011

Study completion Jan 2011

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Nov 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to assess local nasal adverse effects, as well as systemic effects, of PATANASE nasal spray when compared with Patanase Vehicle, pH 3.7 and Patanase Vehicle, pH 7.0 in patients with perennial allergic rhinitis (PAR).

Conditions

  • Perennial Allergic Rhinitis

Interventions

  • Olopatadine hydrochloride 0.6% nasal spray (PATANASE)Drug

    Two sprays in each nostril twice a day (morning and evening) for up to 12 months

  • Olopatadine nasal spray vehicle, pH 3.7Other

    Two sprays in each nostril twice a day (morning and evening) for up to 12 months

  • Olopatadine nasal spray vehicle, pH 7.0Other

    Two sprays in each nostril twice a day (morning and evening) for up to 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Clinically Relevant Change From Baseline (Day 0) in Nasal Examination Parameters to Exit (Month 12 or Sooner)Time frame: Baseline (Day 0), Exit (Month 12 or sooner)
  2. Self-Rated Relief Assessment at Day 30Time frame: Day 30

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Contact Alcon Call Center For Trial Locations

    Fort Worth, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.